Brief: United Therapeutics Fully Enrolls Teton 1 Study Of Inhaled Treprostinil For Idiopathic Pulmonary Fibrosis
04/02/2025 12:28
Feb 4 (Reuters) - United Therapeutics Corp UTHR.O :
* UNITED THERAPEUTICS CORPORATION ANNOUNCES FULL ENROLLMENT
OF THE
TETON 1 STUDY OF INHALED TREPROSTINIL FOR THE TREATMENT OF
IDIOPATHIC PULMONARY FIBROSIS
* UNITED THERAPEUTICS CORP - TOP LINE DATA EXPECTED IN FIRST
HALF
OF 2026
Source text: ID:nBw8RKwQ5a
Further company coverage: UTHR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on United Therapeutics
See all newsBrief: United Therapeutics Corporation Announces Additional $2 Billion Share Repurchase Authorization
Brief: United Therapeutics Announces FDA Clearance To Proceed With Summit Clinical Trial For Treprostinil Smi In Ph-Copd
Liquidia surges as United Therapeutics settlement removes key litigation risk (updated)
Brief: United Therapeutics Enters Settlement Agreement With Liquidia To Resolve Litigation - SEC Filing
Liquidia surges after $381 million settlement with United Therapeutics for lung disease drug